# Cencora, Inc.: Form 10-Q for the period ended Dec 31, 2015

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2016-02-04
- Accepted by EDGAR: Feb 4, 2016, 19:54 ET
- Period: 2015-12-31
- Accession: 0001104659-16-093922
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000110465916093922/a15-24181_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000110465916093922/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-10-01 to 2015-12-31 | $36.71bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-10-01 to 2015-12-31 | $35.74bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2015-10-01 to 2015-12-31 | $964.9m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2015-10-01 to 2015-12-31 | $528.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-10-01 to 2015-12-31 | −$179.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2015-10-01 to 2015-12-31 | −$540.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-10-01 to 2015-12-31 | $330.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-10-01 to 2015-12-31 | $1.46 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-10-01 to 2015-12-31 | $1.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-10-01 to 2015-12-31 | 226,718,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 3 months, 2015-10-01 to 2015-12-31 | $90.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2015-10-01 to 2015-12-31 | $71.2m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2015-10-01 to 2015-12-31 | $118.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2015-12-31 | $978.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-12-31 | $20.36bn | us-gaap:AssetsCurrent |
| Total assets | at 2015-12-31 | $30.76bn | us-gaap:Assets |
| Current liabilities | at 2015-12-31 | $24.02bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2015-12-31 | $4.39bn | us-gaap:LongTermDebt |
| Short-term borrowings | at 2015-12-31 | $108.4m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2015-12-31 | $1.30bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 51,231 characters.

### Overview

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015.

We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution reportable segment and Other.

### Pharmaceutical Distribution Segment

The Pharmaceutical Distribution reportable segment is comprised of two operating segments, which include the operations of AmerisourceBergen Drug Corporation (“ABDC”) and AmerisourceBergen Specialty Group (“ABSG”). Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment’s operations provide drug distribution and related services designed to reduce healthcare costs and improve patient outcomes.

ABDC distributes a comprehensive offering of brand-name and generic pharmaceuticals (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and other consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.

ABSG, through a number of operating businesses, provides pharmaceutical distribution and other services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty products. Additionally, ABSG provides third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers.

Our use of the terms “specialty” and “specialty pharmaceutical products” refers to drugs used to treat complex diseases, such as cancer, diabetes and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms “specialty” and “specialty pharmaceutical products” are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as we do.

Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG’s distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC’s distribution centers results in revenue reported under ABDC. Essentially all of ABSG sales consist of specialty pharmaceutical products. ABDC sales of specialty pharmaceutical products have historically been a relatively small component of its overall revenue.

### Other

Other consists of the AmerisourceBergen Consulting Services (“ABCS”) operating segment, the World Courier Group, Inc. (“World Courier”) operating segment, and the MWI Veterinary Supply, Inc. (“MWI”) operating segment. The results of operations of these operating segments are not significant enough to require separate reportable segment disclosure, and therefore, have been included in “Other” for the purpose of our reportable segment presentation.

ABCS, through a number of operating businesses, provides commercialization support services including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets.

### Recent Developments

On November 6, 2015, we acquired PharMEDium Healthcare Holdings, Inc. (“PharMEDium”), a privately held leading national provider of outsourced compounded sterile preparations to acute care hospitals in the United States, for $2.7 billion in cash, which included certain purchase price adjustments. We financed the transaction through a combination of cash and long-term debt. In November 2015, we entered into a $1.0 billion variable rate term loan, which matures in November 2020 and is subject to quarterly principal payments, as defined. PharMEDium is a component of ABDC within our Pharmaceutical Distribution reportable segment.

### Executive Summary

This executive summary provides highlights from the results of operations that follows:

- Revenue increased 9.3% from the prior year quarter as a result of ABDC’s increased sales of brand and generic products, the strong revenue growth of ABSG and the addition of MWI, which was acquired in February 2015;
- Pharmaceutical Distribution gross profit increased 2.6% from the prior year quarter as the result of ABDC’s and ABSG’s revenue growth, the incremental income from ABDC’s participation in the WBA global sourcing arrangement, and the contribution from our recent PharMEDium acquisition. Gross profit growth in the current year quarter was adversely impacted by lower generic price appreciation and the renewal of our contract with the Department of Defense (“DOD”) at less favorable terms;
- Total gross profit increased 28.3% primarily due to the addition of MWI and a reduction in LIFO expense, which was $101.6 million in the current year quarter in comparison to $144.0 million in the prior year quarter. The decrease in LIFO expense was primarily due to lower brand inflation and higher generic drug deflation;
- Distribution, selling, and administrative expenses increased 26.8% in the quarter primarily due to the addition of MWI and to support our revenue growth;
- Total operating expenses were impacted by an increase in Warrant expense of $96.0 million, a pension settlement charge of $48.7 million, and an increase in depreciation and amortization expense of $32.1 million. Warrant expense increased significantly due to the rise in our stock price during the quarter ended December 31, 2015. We incurred the pension charge in the current year quarter in connection with the settlement of our salaried defined benefit pension plan;
- Total segment operating income increased by 9.1% compared to the prior year quarter primarily due to the addition of MWI; and
- Income taxes were a benefit of $540.8 million in the current year quarter as compared to an expense of $92.9 million in the prior year quarter. In November 2015, we received a private letter ruling, which entitles us to an income tax deduction equal to the fair value of the Warrants at the date of exercise. As a result, we recognized a tax benefit adjustment of approximately $456 million,

which represented the estimated tax deduction for the increase in the value of the Warrants from the issuance date through September 30, 2015. This tax benefit adjustment had a significant impact to our effective tax rate in the quarter ended December 31, 2015. An additional tax benefit of approximately $173 million was recognized primarily related to the change in the fair value of the Warrants during the three months ended December 31, 2015.

### Results of Operations

### Revenue

*(dollars in thousands)*

|  | Three months ended December 31, 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Pharmaceutical Distribution | $35,194,679 | $32,982,724 | 6.7% |
| Other | 1,577,815 | 696,001 | 126.7% |
| Intersegment eliminations | (63,448) | (90,123) | (29.6)% |
| Revenue | $36,709,046 | $33,588,602 | 9.3% |

Revenue increased by 9.3% from the prior year quarter. See discussions below under “Pharmaceutical Distribution” and “Other” for commentary regarding our revenue growth.

We continue to expect our revenue in fiscal 2016 to increase in the range of 8% to 10%. Our future revenue growth will continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers, price increases and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in Federal government rules and regulations.

#### Pharmaceutical Distribution Segment

The Pharmaceutical Distribution segment grew its revenue by 6.7% from the prior year quarter. Intrasegment revenues between ABDC and ABSG have been eliminated in the presentation of total Pharmaceutical Distribution revenue. Intrasegment revenues primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC’s facilities. Intrasegment revenues were $1.7 billion and $1.6 billion in the quarters ended December 31, 2015 and 2014, respectively.

ABDC’s revenue of $30.1 billion in the quarter ended December 31, 2015 increased 5.2% from the prior year quarter (before intrasegment eliminations). The increase in ABDC’s revenue was primarily due to overall market growth including sales to WBA, and increased sales of products that treat Hepatitis C.

ABSG’s revenue of $6.8 billion in the quarter ended December 31, 2015 increased 14.6% from the prior quarter (before intrasegment eliminations). The increase in ABSG’s revenue was due to the continued growth in our oncology business (including an increase in sales to community oncologists) and in our blood products, vaccine and physician office distribution businesses.

A number of our contracts with customers, including group purchasing organizations (“GPOs”), are typically subject to expiration each year. We may lose a significant customer if any existing contract with such customer expires without being extended, renewed, or replaced. During the quarter ended December 31, 2015, no significant contracts expired. Over the next twelve months, the two significant contracts scheduled to expire are our contracts with Kaiser Permanente (“Kaiser”), which expires in June 2016, and Express Scripts, which expires in September 2016. Our revenue, results of operations, and cash flows may be negatively impacted if the Kaiser or Express Scripts contracts are not renewed or the terms of the renewed contracts are less favorable than the existing contracts. Additionally, from time to time, other significant contracts may be renewed prior to their expiration dates. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

#### Other

Revenue in Other increased 126.7% from the prior year quarter primarily due to the revenue contribution from MWI.

### Gross Profit

*(dollars in thousands)*

|  | Three months ended December 31, 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Pharmaceutical Distribution | $771,968 | $752,056 | 2.6% |
| Other | 281,680 | 144,267 | 95.2% |
| Gains on antitrust litigation settlements | 12,791 | — |  |
| LIFO expense | (101,562) | (144,024) |  |
| Gross profit | $964,877 | $752,299 | 28.3% |

Gross profit increased 28.3%, or $212.6 million from the prior year quarter. The increase was due to the increase in Pharmaceutical Distribution gross profit, the increase in the gross profit of Other, gains on antitrust litigation settlements, and the $42.5 million decrease in LIFO expense from the prior year quarter. The decrease in LIFO expense was primarily due to lower brand inflation and higher generic drug deflation.

Pharmaceutical Distribution gross profit increased 2.6%, or $19.9 million, from the prior year quarter. The increase was due to higher brand and generic sales volume largely attributable to WBA (as noted above). Gross profit also increased due to an increase in income resulting from our participation in the WBA global sourcing arrangement, the contribution from our recent PharMEDium acquisition, and the growth of our specialty distribution businesses. Gross profit growth in the current year quarter was adversely impacted by lower generic price appreciation and the renewal of our contract with the DOD at less favorable terms. As a percentage of revenue, Pharmaceutical Distribution gross profit margin of 2.19% in the quarter ended December 31, 2015 decreased 9 basis points from the prior year quarter. The decrease was primarily due to a decline in generic price appreciation and the DOD contract renewal.

Gross profit in Other increased 95.2%, or $137.4 million, from the prior year quarter. The increase was primarily due to the contribution from our February 2015 acquisition of MWI, and, to a lesser extent, the increase in ABCS’s revenue. As a percentage of revenue, gross profit margin in Other of 17.85% in the quarter ended December 31, 2015 decreased from 20.73% in the prior year quarter. The decrease was primarily due to the addition of MWI and the increase in ABCS distribution revenue, both of which have lower gross profit margins in comparison to other businesses within Other.

We recognized gains of $12.8 million from antitrust litigation settlements with pharmaceutical manufacturers during the quarter ended December 31, 2015. The gains were recorded as reductions to cost of goods sold. There were no gains in the quarter ended December 31, 2014.

Our cost of goods sold for interim periods includes a last-in, first-out (“LIFO”) provision that is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by expected changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to our annual LIFO provision.

### Operating Expenses

*(dollars in thousands)*

|  | Three months ended December 31, 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Distribution, selling and administrative | $528,296 | $416,491 | 26.8% |
| Depreciation and amortization | 81,438 | 49,297 | 65.2% |
| Warrants | 467,375 | 371,405 |  |
| Employee severance, litigation and other | 18,868 | 3,503 |  |
| Pension settlement charge | 48,731 | — |  |
| Total operating expenses | $1,144,708 | $840,696 |  |

Distribution, selling and administrative expenses increased 26.8%, or $111.8 million, from the prior year quarter, primarily due to our February 2015 acquisition of MWI. In addition, Pharmaceutical Distribution operating expenses, including technology spend, during the current year quarter were higher to support the growth in our business. As a percentage of revenue, distribution, selling and administrative expenses were 1.44% in the current year quarter and represents an increase of 20 basis points in comparison to the prior year quarter. The increase was primarily due to the addition of MWI, which has higher operating expenses as a percentage of revenue in comparison to the Pharmaceutical Distribution segment.

Depreciation expense increased from the prior year quarter due to an increase in the amount of capital projects being depreciated. Amortization expense increased from prior year quarter primarily due to the amortization of intangible assets from our MWI and PharMEDium acquisitions.

Warrant expense increased significantly from the prior year quarter primarily due to the rise in our stock price during the quarter ended December 31, 2015. The Warrants were issued in March 2013 in connection with the agreements and arrangements that define our strategic relationship with WBA. Warrant expense is largely dependent upon changes in our stock price, therefore, future Warrant expense could fluctuate significantly. (Refer to “Critical Accounting Policies and Estimates — Warrants” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015 for a more detailed description of the accounting for the Warrants.)

Employee severance, litigation and other for the quarter ended December 31, 2015 included $16.1 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition) and $2.8 million of employee severance and other costs. Employee severance, litigation and other for the quarter ended December 31, 2014 included $3.0 million of deal-related transaction costs and $0.5 million of employee severance and other costs.

We recorded a pension settlement charge of $48.7 million in the quarter ended December 31, 2015 related to the settlement of our salaried defined benefit plan (see Note 7).

### Operating Income

*(dollars in thousands)*

|  | Three months ended December 31, 2015 | 2014 | Change |
| --- | ---: | ---: | ---: |
| Pharmaceutical Distribution | $379,559 | $390,401 | -2.8% |
| Other | 95,565 | 45,166 | 111.6% |
| Total segment operating income | 475,124 | 435,567 | 9.1% |
| Gains on antitrust litigation settlements | 12,791 | — |  |
| LIFO expense | (101,562) | (144,024) |  |
| Acquisition-related intangibles amortization | (31,210) | (5,032) |  |
| Warrant expense | (467,375) | (371,405) |  |
| Employee severance, litigation and other | (18,868) | (3,503) |  |
| Pension settlement charge | (48,731) | — |  |
| Operating loss | $(179,831) | $(88,397) |  |

Segment operating income is evaluated before gains on antitrust litigation settlements; LIFO expense; acquisition-related intangibles amortization; Warrant expense; employee severance, litigation and other; and the pension settlement charge.

Pharmaceutical Distribution operating income decreased 2.8%, or $10.8 million, from the prior year quarter due to the increase in operating expenses, offset in part by the increase in gross profit from the prior year quarter. As a percentage of revenue, Pharmaceutical Distribution operating income margin decreased 10 basis points from the prior year quarter primarily due to a decrease in generic price appreciation and the DOD contract renewal.

Operating income in Other increased 111.6%, or $50.4 million, from the prior year quarter primarily due to the February 2015 acquisition of MWI.

Total operating loss for the quarters ended December 31, 2015 and 2014 was driven by the significant Warrant expense resulting from the rise in our stock price during the quarters ended December 31, 2015 and 2014.

Interest expense, interest income, and the respective weighted average interest rates in the quarters ended December 31, 2015 and 2014 were as follows (in thousands):

|  | 2015 Amount | Weighted Average Interest Rate | 2014 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $31,587 | 2.76% | $17,891 | 3.05% |
| Interest income | (708) | 0.28% | (549) | 0.17% |
| Interest expense, net | $30,879 |  | $17,342 |  |

Interest expense, net, increased 78.1%, or $13.5 million, from the prior year quarter due to an increase of $2.1 billion in average borrowings primarily due to the February 2015 issuance of senior notes totaling $1.0 billion and the February 2015 and November 2015 variable-rate term loan borrowings to finance a portion of the MWI and PharMEDium acquisitions, respectively. Our average borrowing rate was lower during the current year quarter primarily as a result of the recent variable-rate financings, which bear interest at lower rates.

Income taxes were a benefit of $540.8 million in the quarter ended December 31, 2015 as compared to an expense of $92.9 million in the prior year quarter and were determined based on our taxable income. In November 2015, we received a private letter ruling from the Internal Revenue Service, which entitles us to an income tax deduction equal to the fair value of the Warrants on the date of exercise. As a result, we recognized a tax benefit adjustment of approximately $456 million, which represented the estimated tax deduction for the increase in the fair value of the Warrants from the issuance date through September 30, 2015. This tax benefit adjustment had a significant impact to our effective tax rate in the quarter ended December 31, 2015. An additional tax benefit of approximately $173 million was recognized primarily related to the change in the fair value of the Warrants during the three months ended December 31, 2015.

Net income was $330.4 million in the quarter ended December 31, 2015 compared to a net loss of $199.9 million in the prior year quarter and was primarily due to the income tax benefit associated with the Warrants, as described above.

### Liquidity and Capital Resources

The following table illustrates our debt structure at December 31, 2015, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note and the overdraft facility (in thousands):

| Fixed-Rate Debt: | Outstanding Balance | Additional Availability |
| --- | ---: | ---: |
| $600,000, 1.15% senior notes due 2017 | $599,712 | $— |
| $400,000, 4.875% senior notes due 2019 | 398,543 | — |
| $500,000, 3.50% senior notes due 2021 | 499,586 | — |
| $500,000, 3.40% senior notes due 2024 | 498,812 | — |
| $500,000, 3.25% senior notes due 2025 | 497,570 | — |
| $500,000, 4.25% senior notes due 2045 | 499,094 | — |
| Total fixed-rate debt | 2,993,317 | — |
| **Variable-Rate Debt:** |  |  |
| Term loans | 1,500,000 | — |
| Multi-currency revolving credit facility due 2020 | — | 1,400,000 |
| Receivables securitization facility due 2018 | — | 950,000 |
| Revolving credit note | — | 75,000 |
| Overdraft facility (£20,000) | 8,412 | 21,060 |
| Total variable-rate debt | 1,508,412 | 2,446,060 |
| Total debt | $4,501,729 | $2,446,060 |

Along with our cash balances, our aggregate availability under our multi-currency revolving credit facility, our receivables securitization facility, our revolving credit note, and our overdraft facility provide us sufficient sources of capital to fund our working capital requirements and other strategic initiatives. We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, can require the use of our credit facilities to fund short-term capital needs. Our cash balance in the quarter ended December 31, 2015 needed to be supplemented by intra-period credit facility borrowings to cover a portion of the purchase price of PharMEDium in advance of securing long-term financing and to cover short-term working capital needs. The largest amount of intra-period borrowings under our revolver and securitization credit facilities that was outstanding at any one time during the quarter ended December 31, 2015 was $1,018.2 million. All but $8.4 million of the $1,755.3 million of cumulative intra-period borrowings under our credit facilities during the quarter ended December 31, 2015 were repaid by the end of the quarter.

We have a $1.4 billion multi-currency senior unsecured revolving credit facility, which expires in November 2020, (the “Multi-Currency Revolving Credit Facility”) with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 69 basis points to 110 basis points over LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over LIBOR / EURIBOR / Bankers Acceptance

Stamping Fee at December 31, 2015). Additionally, interest on borrowings denominated in Canadian dollars may accrue at either the Canadian prime rate or the CDOR rate. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 6 basis points to 15 basis points, annually, of the total commitment (9 basis points at December 31, 2015). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, which we are compliant with as of December 31, 2015.

We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program at December 31, 2015.

We have a $950 million receivables securitization facility (“Receivables Securitization Facility”), which expires in November 2018. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, which we are compliant with as of December 31, 2015.

We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note (“Revolving Credit Note”). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have an uncommitted U.K. overdraft facility (“Overdraft Facility”), which allows us to borrow up to £20 million to fund short term normal trading cycle fluctuations related to our MWI business. The Overdraft Facility expires in November 2016.

In February 2015, we entered into a variable-rate term loan (“February 2015 Term Loan”), which matures in 2020. In fiscal 2015, we elected to make principal payments of $500 million on the February 2015 Term Loan, and as a result, our next required principal payment is due upon maturity. The February 2015 Term Loan bears interest at a rate equal either to a base rate plus a margin or a LIBOR plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over a LIBOR (100 basis points at December 31, 2015) and 0 to 25 basis points over a base rate. The February 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we are compliant with as of December 31, 2015.

In November 2015, we entered into a $1.0 billion variable-rate term loan (the “November 2015 Term Loan”), which matures in 2020. The November 2015 Term Loan is subject to quarterly principal payments of $25 million on the last business day of each March, June, September and December, commencing in March 2016. The remaining unpaid principal amount of the November 2015 Term Loan is due on the maturity date. The November 2015 Term Loan will bear interest at a rate equal either to a base rate, plus a margin, or a LIBOR, plus a margin. The margin will be based on our public debt ratings and ranges from 0 basis points to 25 basis points over a base rate, and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points at December 31, 2015). The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we are compliant as of December 31, 2015. We used the proceeds from the November 2015 Term Loan to finance a portion of the cash consideration paid in connection with the acquisition of PharMEDium.

Our operating results have generated cash flow, which, together with availability under our debt agreements and credit terms from suppliers, has provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, repurchases of shares of our common stock, and our hedging strategy (see below for further details).

Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.

In August 2013, our board of directors approved a program allowing us to purchase up to $750 million in shares of our common stock, subject to market conditions. During the quarter ended December 31, 2015, none of our common stock was purchased under this share repurchase program. As of December 31, 2015, we had $274.5 million of availability remaining on the $750 million repurchase program.

If subsidiaries of WBA exercise their right to purchase our common stock pursuant to the Warrants that we issued to them, the future issuances of shares of our common stock upon exercise of the Warrants will dilute the ownership interests of our then-existing stockholders and could adversely affect the market price of our common stock. We have taken steps to mitigate the potentially dilutive effect that exercise of the Warrants could have by hedging a portion of our future obligation to deliver common stock with a financial institution and repurchasing additional shares of our common stock for our own account over time.

In June 2013, we commenced our hedging strategy by entering into a contract with a financial institution pursuant to which it has executed a series of issuer capped call transactions (“Capped Calls”). The Capped Calls give us the right to buy shares of our common stock subject to the Warrants at specified prices at maturity, should the Warrants be exercised in 2016 and 2017 and were initially intended to cover approximately 60% of the shares subject to the Warrants at the time we entered into the transactions. If the Warrants are exercised, we will use a majority of the proceeds to repurchase our shares under the Capped Calls. If our share price exceeds the “cap” price in the Capped Calls at the time the Warrants are exercised, the number of shares that will be delivered to us under the Capped Calls will be reduced, and accordingly, will cover less than 60% of the shares of common stock subject to the Warrants. In addition, if our future share price at the exercise dates is lower than our breakeven share price, then our purchase of the Capped Calls will have been an ineffective use of capital. We completed this hedge transaction in January 2014. In total, under the hedge transaction, we purchased Capped Calls on 27.2 million shares of our common stock for a total premium of $368.7 million.

Subsequently, we amended certain of the Capped Calls to increase their “cap” price to continue to address the potentially dilutive effect of the Warrants. We paid a premium of $100.0 million in January 2015 to increase the cap price on certain of the Capped Calls subject to the warrants that become exercisable in 2016.

In fiscal 2014 and 2015, we purchased $1,774.1 million of our common stock under special share repurchase programs as an opportunity to further mitigate the potentially dilutive effect of the Warrants and supplement our previously executed warrant hedging strategy.

In March 2015, we supplemented our hedging strategy by entering into a contract with a financial institution pursuant to which it has executed a series of issuer call options (“Call Options”). The Call Options give us the right to buy shares of our common stock subject to the Warrants at specified prices between April 2015 and October 2015. In total, we purchased Call Options on six million shares of our common stock for a total premium of $80.0 million. In the three months ended December 31, 2015, we exercised 1.3 million of the Call Options for $118.6 million, which reduced the availability under our special share repurchase programs.

In September 2015, our board of directors approved a new special share repurchase program allowing us to repurchase up to $2.4 billion in shares of our common stock, subject to market conditions, to further mitigate the potentially dilutive effect of the Warrants as part of our warrant hedging strategy. During the quarter ended December 31, 2015, we purchased $118.6 million of our common stock under this program (all under the Call Options). As of December 31, 2015, we had $2,157.3 million of availability remaining on this program.

Based on the closing price of our Common Stock on December 31, 2015, the Capped Calls associated with the Warrants exercisable in 2016 would have covered approximately 51% of the shares subject to the Warrants and the Capped Calls associated with the Warrants exercisable in 2017 would have covered approximately 46% of the shares subject to the Warrants. Adding the shares repurchased through December 31, 2015 under the special share repurchase programs, we would have covered 100% of the Warrants exercisable in 2016 and approximately 85% of the Warrants exercisable in 2017. For every five dollar increase in the price of our Common Stock, the coverage provided by the Capped Calls on each Warrant will decrease by approximately two percent, and for every five dollar decrease in the price of our Common Stock, the coverage provided by the Capped Calls on each Warrant will increase by approximately two percent.

To the extent the Capped Calls, share repurchases and Call Options do not fully mitigate the dilutive effect of the Warrants, we intend to consider repurchasing additional shares of our common stock and other measures, which may include additional amendments to the Capped Calls or the purchase of additional Call Options. The amount of dilution that we would be able to mitigate will depend on the relative costs and benefits of such a transaction, considering factors such as: our financial performance, the current and future share price of our common stock, our expected cash flows, competing priorities for capital, and overall market conditions.

We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. In the quarter ended December 31, 2015, we used a $1.0 billion variable rate term loan to finance a portion of the PharMEDium acquisition price. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and on terms acceptable to us. There were no such financial instruments in effect at December 31, 2015.

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $978.1 million in cash and cash equivalents at December 31, 2015. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.

We are exposed to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Canadian Dollar, and the Brazilian Real. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. As of December 31, 2015, we had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of a C$44.5 million outstanding note that we received in conjunction with the sale of a Canadian business in May 2013.

Changes in the price and volatility of our common stock may have a significant impact on the fair value of the Warrants issued to WBA and the related tax benefit. As of December 31, 2015, a one dollar change in our common stock, holding other assumptions constant, would increase or decrease the fair value of the Warrants by approximately $45 million and a one percent change in volatility, holding other assumptions constant, would have no impact on the fair value of the Warrants.

Following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and minimum payments on our other commitments at December 31, 2015 (in thousands):

|  | Payments Due by Period Total | Within 1 Year | 1-3 Years | 4-5 Years | After 5 Years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt, including interest payments | $5,728,500 | $227,725 | $1,028,276 | $1,801,749 | $2,670,750 |
| Operating leases | 384,404 | 77,890 | 126,532 | 86,978 | 93,004 |
| Other commitments | 83,657 | 39,669 | 40,636 | 3,352 | — |
| Total | $6,196,561 | $345,284 | $1,195,444 | $1,892,079 | $2,763,754 |

We outsource to IBM Global Services a portion of our corporate and ABDC data center operations. The remaining commitment under our arrangement, which expires in June 2018, is approximately $66.7 million as of December 31, 2015, of which $33.5 million represents our commitment over the next twelve months, and is included in “Other commitments” in the above table.

Our liability for uncertain tax positions was $51.9 million (including interest and penalties) as of December 31, 2015. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.

During the quarter ended December 31, 2015, our operating activities provided $750.8 million of cash in comparison to cash provided of $897.0 million in the prior year quarter. Cash provided by operations during the quarter ended December 31, 2015 was principally the result of net income of $330.4 million and an increase in accounts payable, accrued expenses, and income taxes of $1.5 billion, offset, in part by an increase in merchandise inventories of $1.1 billion. The increase in accounts payable, accrued expenses and income taxes was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers. We also increased our merchandise inventories at December 31, 2015 to support the increase in business volume and, consistent with prior years, due to seasonal needs.

We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.

|  | Quarter ended December 31, 2015 | 2014 |
| --- | ---: | ---: |
| Days sales outstanding | 20.8 | 18.8 |
| Days inventory on hand | 29.5 | 30.4 |
| Days payable outstanding | 55.0 | 48.4 |

The increase in days payable outstanding from the prior year quarter has benefited from the increase in purchases of generic pharmaceuticals, which have longer payment terms than brand-name pharmaceuticals.

Our cash flow from operating activities can vary significantly from period to period based on fluctuations in our period end working capital. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. Operating cash uses during the quarter ended December 31, 2015 included $33.6 million of interest payments and $3.0 million of income tax payments, net of refunds.

During the quarter ended December 31, 2014, our operating activities provided $897.0 million of cash. Cash provided by operations during the quarter ended December 31, 2014 was principally the result of an increase in accounts payable, accrued expenses, and income taxes of $3.5 billion and non-cash items of $420.8 million, offset, in part, by the net loss of $199.9 million, an increase in merchandise inventories of $2.1 billion and an increase in accounts receivable of $766.7 million. Accounts receivable increased from September 30, 2014, reflecting our increased revenue volume, including additional sales to WBA. Our accounts receivable balance was also favorably impacted by the timing of cash receipts from our customers. We also increased our merchandise inventories at December 31, 2014 to support the increase in volume and, consistent with prior years, due to seasonal needs. The increase in accounts payable, accrued expenses and income taxes was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers.

Capital expenditures for the quarter ended December 31, 2015 and 2014 were $90.1 million and $52.6 million, respectively. Significant capital expenditures in the quarter ended December 31, 2015 included technology initiatives, including costs related to the development of track-and-trace technology, costs associated with expanding distribution capacity, and expansion of support facilities. We currently expect to spend approximately $400 million for capital expenditures during fiscal 2016. Significant capital expenditures in the quarter ended December 31, 2014 included technology initiatives, including costs related to the further development of our enterprise resource planning (“ERP”) system, costs associated with building our national distribution center, and expansion of support facilities.

Net cash provided by financing activities in fiscal 2015 included $1.0 billion of borrowings under our November 2015 Term Loan. We used the proceeds from this financing activity to fund a portion of our November 2015 acquisition of PharMEDium.

During the quarters ended December 31, 2015 and 2014, we paid $118.6 million and $300.2 million, respectively, for purchases of our common stock.

In November 2014, our board of directors increased the quarterly cash dividend by 23% from $0.235 per share to $0.29 per share. In November 2015, our board of directors increased the quarterly cash dividend by 17% from $0.29 per share to $0.34 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.

### Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: competition; industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; price inflation in branded and generic pharmaceuticals, and price deflation in generics; declining economic conditions in the United States and abroad; financial market volatility and disruption; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; the loss, bankruptcy or insolvency of a major supplier; changes to the customer or supplier mix; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes in any of the economic models used by any of our suppliers to set pricing and/or other terms for the purchase of pharmaceuticals; interest rate and foreign currency exchange rate fluctuations; the disruption of AmerisourceBergen’s cash flow and ability to return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship between Walgreen Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical distribution agreement and/or the global sourcing arrangement; risks associated with the potential impact on AmerisourceBergen’s earnings per share resulting from the issuance of the warrants to subsidiaries of Walgreen Boots Alliance, Inc. (the “Warrants”); AmerisourceBergen’s inability to fully implement its hedging strategy to mitigate the potentially dilutive effect of the issuance of its common stock in accordance with the Warrants under its special share repurchase program due to its financial performance, the current and future share price of its common stock, its expected cash flows, competing priorities for capital, and overall market conditions; changes in the United States healthcare and regulatory environment; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of MWI and PharMEDium, or the inability to capture all of the anticipated synergies related thereto; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen’s tax positions and/or AmerisourceBergen’s tax liabilities or adverse resolution of challenges to AmerisourceBergen’s tax positions; natural disasters or other unexpected events that affect AmerisourceBergen’s operations; the impairment of goodwill or other intangible assets, resulting in a charge to earnings; errors in the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting AmerisourceBergen’s business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report, (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2015 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act.

## Market risk

As filed, 262 characters.

The Company’s most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company’s common stock. See the discussion under “Liquidity and Capital Resources” in Item 2 on page 23.

## Controls and procedures

As filed, 1,507 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

During the first quarter of fiscal 2016, excluding PharMEDium, there was no change in AmerisourceBergen Corporation’s internal control over financial reporting that materially affected, or is reasonably likely to materially affect, internal control over financial reporting. Management is currently evaluating the impact of PharMEDium on AmerisourceBergen’s internal control over financial reporting.

## Risk factors

As filed, 141 characters.

Our significant business risks are described in Item 1A to Form 10-K for the year ended September 30, 2015 to which reference is made herein.

Filed Feb 4, 2016.
Source: SEC EDGAR, the filing index for accession 0001104659-16-093922. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
